Table 1 Pharmacological parameters from fitting agonist curves to the three different models presented in Fig. 6 as estimated by nonlinear regression for each equation
From: Characterization of the GTPγS release function of a G protein-coupled receptor
Stephenson’s Efficacy | Two-State Efficacy | Operational Efficacy | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Emax εBinding | Emax εRelease | LogEC50 Binding | LogEC50 Release | Two-state αBinding | Two-state αRelease | Two-state logKBinding | Two-state logKRelease | Operational τBinding | Operational τRelease | Operational logKBinding | Operational logKRelease | |
DAMGO | 1 | 1 | -8.0 ± 0.04 | -7.8 ± 0.05 | nd | nd | nd | nd | nd | nd | nd | nd |
Morphine | 1.02 ± 0.03a | 0.84 ± 0.01a | -7.5 ± 0.06 | -7.5 ± 0.08 | nde | 511.2 ± 103.9e | nd | -6.7 ± 0.13 | ndh | 6.73 ± 0.13 h | nd | -6.7 ± 0.13 |
Fentanyl | 1.02 ± 0.03b | 0.92 ± 0.01b | -7.6 ± 0.04 | -7.7 ± 0.16 | ndf | 1061 ± 449.1 f | nd | -6.6 ± 0.22 | ndi | 6.56 ± 0.21i | nd | -6.6 ± 0.21 |
Buprenorphine | 0.47 ± 0.02 | 0.51 ± 0.02 | -8.9 ± 0.02 d | -10.1 ± 0.06 d | 100.6 ± 4.3 | 100.6 ± 4.3 | -8.5 ± 0.07 | -9.8 ± 0.07 | 1.04 ± 0.05 | 1.04 ± 0.05 | -8.5 ± 0.1 | -9.8 ± 0.1 |
Nalbuphine | 0.17 ± 0.02c | 0.35 ± 0.05c | -8.0 ± 0.11 | -8.3 ± 0.13 | 20.5 ± 1.02 g | 54.9 ± 5.6 g | -7.8 ± 0.09 | -8.1 ± 0.17 | 0.20 ± 0.01j | 0.54 ± 0.05j | -7.9 ± 0.55 | -8.1 ± 0.14 |